NFKB1 and Miyoshi myopathy: The combination of those NIK inhibitors and IKKβ-inhibitors or dexamethasone may also provide an effective therapeutic strategy to more efficiently target most MM tumors, including tumors that do not have intrinsic mutations in the NFkB pathway, but are dependent on extrinsic ligands that activate the NFkB pathway.